WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study 28 July 2020
Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2 27 July 2020
Pfizer and BioNTech announce agreement with the United Kingdom for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2 27 July 2020
Pfizer and BioNTech granted FDA Fast Track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2 14 July 2020
Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2 01 July 2020
Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program 11 May 2020
Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development 10 April 2020
Pfizer Vaccines launches global Centers of Excellence Network 23 January 2020
Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program 23 December 2019
FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions 02 December 2019
Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination 13 November 2019
OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon 24 October 2019
Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx 07 October 2019
Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman 30 September 2019
Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina 29 August 2019
The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance 21 August 2019
Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine 29 July 2019
Pfizer completes acquisition of Therachon 05 July 2019
Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development 07 June 2019
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures 24 May 2019
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech commence global clinical trial to evaluate COVID-19 vaccine in pregnant women

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.